サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1790178

米国のPOC分子診断の市場規模、シェア、動向分析レポート：技術別、用途別、検査場所別、最終用途別、セグメント予測、2025～2033年

U.S. Point of Care Molecular Diagnostics Market Size, Share & Trends Analysis Report By Test Location, By Application, By Technology, By End-use, And Segment Forecasts, 2025 - 2033

出版日
ページ情報
英文 150 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.73円
米国のPOC分子診断の市場規模、シェア、動向分析レポート：技術別、用途別、検査場所別、最終用途別、セグメント予測、2025～2033年
出版日: 2025年07月28日
発行: Grand View Research
ページ情報: 英文 150 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

市場規模と動向：

米国のPOC分子診断の市場規模は2024年に32億3,000万米ドルと推定され、2025～2033年にかけてCAGR 5.45％で成長すると予測されています。

同市場の中心は、迅速かつ分散化された分子検査であり、患者の治療現場またはその近くで、より迅速な臨床判断をサポートします。これらの診断プラットフォームは、感染症スクリーニング、呼吸器感染症、性感染症検出などの用途で採用が拡大しており、外来患者や救急医療現場での迅速かつ正確な結果に対するニーズがその原動力となっています。

市場の成長を支えているのは、特に救急外来や診療所など、従来の検査室以外での迅速かつ簡便な検査に対する需要の高まりです。感染症症例の増加と迅速な結果へのニーズが、ポイントオブケア（POC）分子検査の使用を後押ししています。ポータブルPCR装置やシンプルなサンプル処理ツールなどの新技術により、これらの検査はより正確で使いやすくなっています。加えて、COVID-19パンデミック後の迅速検査への注目が、市場のさらなる成長を後押ししています。

さらに、プライマリケアの現場におけるPOC分子診断は、基本的なグルコース検査からより複雑な血液凝固チェックまで、幅広い用途をカバーしています。米国中の多くのクリニックが、従来のラボベースの検査からPOC方式に移行しており、サンプルの取り扱いや輸送に関連する遅延の軽減に役立っています。この切り替えにより、患者の診察時に迅速な判断が可能となり、より迅速な結果、低コスト、ケアの向上につながります。

さらに、高齢者人口の増加が米国のPOC分子診断産業の成長を支えるものと期待されています。米国国立がん研究所のSEERデータベースによると、女性の38％、男性の43％が生涯のうちにがんに罹患する可能性があります。また、新たに発症するがんの3分の2近くが65歳以上の高齢者であり、加齢によってがんに対する脆弱性が増すことを示しています。分子診断は、がん、感染症、心臓病の治療に重要な役割を果たしており、高齢者のタイムリーな診断と治療に欠かせないものとなっています。

さらに、市場各社は拡大する診断ニーズに対応するため、新しいPOC分子検査製品の開発に積極的に取り組んでいます。2023年4月、ロサンゼルスを拠点とするCurative, Inc.は、Sensible Diagnosticsのスピンオフを発表し、デスクトップPCR検査プラットフォームを商品化しました。このシステムは、ラテラルフロー抗原検査と同程度のコストで、約10分でラボ品質の結果が得られるように設計されています。小売クリニック、急患センター、その他患者に近い環境での使用を想定しています。

2023年8月、Sensible Diagnosticsは、POC用のマルチプレックス呼吸器ウイルスパネルの開発を支援するため、約100万米ドルのNIH RADx Tech賞を受賞しました。このような取り組みは、タイムリーな診断をサポートし、分散化された医療環境全体の臨床ワークフローを改善する、迅速で正確な分子検査ソリューションへの投資が拡大していることを反映しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 米国のPOC分子診断市場の変数、動向、範囲

  • 市場系統の展望
    • 親市場の展望
    • 関連/付随市場の展望
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • 米国のPOC分子診断市場の分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析

第4章 米国のPOC分子診断市場:技術別、推定・動向分析

  • 変動分析：技術別
  • PCRベース
    • PCRベース市場、2021～2033年
  • 遺伝子シーケンシングベース
    • 遺伝子シーケンシングベース市場、2021～2033年
  • ハイブリダイゼーションベース
    • ハイブリダイゼーションベース市場、2021～2033年
  • マイクロアレイベース
    • マイクロアレイベース市場、2021～2033年

第5章 米国のPOC分子診断市場:用途別、推定・動向分析

  • 変動分析：用途別
  • 感染症
    • 感染症市場、2021～2033年
    • HIV POC
    • クロストリジウム・ディフィシルPOC
    • HBV POC
    • 肺炎または連鎖球菌関連感染症
    • 呼吸器合胞体ウイルス（RSV）POC
    • HPV POC
    • インフルエンザ/インフルエンザPOC
    • HCV POC
    • MRSA POC
    • 結核および薬剤耐性結核のPOC
    • HSV POC
    • その他
  • 腫瘍学
    • 腫瘍学市場、2021～2033年
  • 血液学
    • 血液学市場、2021～2033年
    • 全血球数（CBC）
    • プロトロンビン時間（PT）
    • 部分トロンボプラスチン時間（PTT）
    • その他
  • 出生前検査
    • 出生前検査市場、2021～2033年
  • 内分泌学
    • 内分泌学市場、2021～2033年
  • その他
    • その他市場、2021～2033年

第6章 米国のPOC分子診断市場:検査場所別、推定・動向分析

  • 変動分析：検査場所別
  • OTC
    • OTC市場、2021～2033年
  • POC
    • POC市場、2021～2033年

第7章 米国のPOC分子診断市場:最終用途別、推定・動向分析

  • 変動分析：最終用途別
  • 分散型ラボ
    • 分散型ラボ市場、2021～2033年
  • 病院
    • 病院市場、2021～2033年
  • ホームケア
    • ホームケア市場、2021～2033年
  • 介護付きヘルスケア施設
    • 介護付きヘルスケア施設市場、2021～2033年
  • その他
    • その他市場、2021～2033年

第8章 競合情勢

  • 企業分類
  • 戦略マッピング
    • 新製品・新サービスの発売
    • パートナーシップ
    • 取得
    • コラボレーション
    • 資金調達
  • 主要企業の市場シェア分析（2024年）
  • 企業ヒートマップ分析
  • 企業プロファイル
    • QIAGEN
    • DANAHER
    • THERMO FISHER SCIENTIFIC, INC.
    • BD
    • F. HOFFMAN-LA ROCHE AG
    • CHARLES RIVER LABORATORIES
    • QUEST DIAGNOSTICS INCORPORATED
    • BIO-RAD LABORATORIES, INC.
    • HOLOGIC INC.
    • AGILENT TECHNOLOGIES, INC.
図表

List of Tables

  • Table 1 List of abbreviations
  • Table 2 U.S. Point-of-Care Molecular Diagnostics market, by test location, 2021 - 2033 (USD Million)
  • Table 3 U.S. Point-of-Care Molecular Diagnostics market, by application, 2021- 2033 (USD Million)
  • Table 4 U.S. Point-of-Care Molecular Diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 5 U.S. Point-of-Care Molecular Diagnostics market, by end use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in the U.S.
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 U.S. Point-of-Care Molecular Diagnostics market: market outlook
  • Fig. 10 U.S. Point-of-Care Molecular Diagnostics competitive insights
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Penetration and growth prospect mapping
  • Fig. 14 Industry value chain analysis
  • Fig. 15 U.S. Point-of-Care Molecular Diagnostics market driver impact
  • Fig. 16 U.S. Point-of-Care Molecular Diagnostics market restraint impact
  • Fig. 17 U.S. Point-of-Care Molecular Diagnostics market strategic initiatives analysis
  • Fig. 18 U.S. Point-of-Care Molecular Diagnostics market: Application movement analysis
  • Fig. 19 U.S. Point-of-Care Molecular Diagnostics market: Application outlook and key takeaways
  • Fig. 20 Point-of-Care Molecular Diagnostics Infectious Diseases market, 2021 - 2033 (USD Million)
  • Fig. 21 Point-of-Care Molecular Diagnostics HIV POC market, 2021 - 2033 (USD Million)
  • Fig. 22 Point-of-Care Molecular Diagnostics Clostridium difficile POC market, 2021 - 2033 (USD Million)
  • Fig. 23 Point-of-Care Molecular Diagnostics HBV POC market, 2021 - 2033 (USD Million)
  • Fig. 24 Point-of-Care Molecular Diagnostics Pneumonia or Streptococcus associated infections market, 2021 - 2033 (USD Million)
  • Fig. 25 Point-of-Care Molecular Diagnostics Respiratory syncytial virus (RSV) POC market, 2021 - 2033 (USD Million)
  • Fig. 26 Point-of-Care Molecular Diagnostics HPV POC market, 2021 - 2033 (USD Million)
  • Fig. 27 Point-of-Care Molecular Diagnostics Influenza/Flu POC market, 2021 - 2033 (USD Million)
  • Fig. 28 Point-of-Care Molecular Diagnostics HCV POC market, 2021 - 2033 (USD Million)
  • Fig. 29 Point-of-Care Molecular Diagnostics MRSA POC market, 2021 - 2033 (USD Million)
  • Fig. 30 Point-of-Care Molecular Diagnostics TB and drug-resistant TB POC market, 2021 - 2033 (USD Million)
  • Fig. 31 Point-of-Care Molecular Diagnostics HSV POC market, 2021 - 2033 (USD Million)
  • Fig. 32 Point-of-Care Molecular Diagnostics Other Infectious Diseases market, 2021 - 2033 (USD Million)
  • Fig. 33 Point-of-Care Molecular Diagnostics Oncology market, 2021 - 2033 (USD Million)
  • Fig. 34 Point-of-Care Molecular Diagnostics Hematology market, 2021 - 2033 (USD Million)
  • Fig. 35 Point-of-Care Molecular Diagnostics Complete blood count (CBC) market, 2021 - 2033 (USD Million)
  • Fig. 36 Point-of-Care Molecular Diagnostics Prothrombin time (PT) market, 2021 - 2033 (USD Million)
  • Fig. 37 Point-of-Care Molecular Diagnostics Partial Thromboplastin Time (PTT) market, 2021 - 2033 (USD Million)
  • Fig. 38 Point-of-Care Molecular Diagnostics Others market, 2021 - 2033 (USD Million)
  • Fig. 39 Point-of-Care Molecular Diagnostics Prenatal Testing market, 2021 - 2033 (USD Million)
  • Fig. 40 Point-of-Care Molecular Diagnostics Endocrinology market, 2021 - 2033 (USD Million)
  • Fig. 41 Point-of-Care Molecular Diagnostics Other Applications market, 2021 - 2033 (USD Million)
  • Fig. 42 U.S. Point-of-Care Molecular Diagnostics market: Technology movement Analysis
  • Fig. 43 U.S. Point-of-Care Molecular Diagnostics market: Technology outlook and key takeaways
  • Fig. 44 Point-of-Care Molecular Diagnostics PCR-based market, 2021 - 2033 (USD Million)
  • Fig. 45 Point-of-Care Molecular Diagnostics Genetic Sequencing-based market, 2021 - 2033 (USD Million)
  • Fig. 46 Point-of-Care Molecular Diagnostics Hybridization-based market, 2021 - 2033 (USD Million)
  • Fig. 47 Point-of-Care Molecular Diagnostics Microarray-based market, 2021 - 2033 (USD Million)
  • Fig. 48 Point-of-care Molecular Diagnostics revenue share, by test location, 2021 - 2033
  • Fig. 49 Point-of-Care Molecular Diagnostics OTC market, 2021 - 2033 (USD Million)
  • Fig. 50 Point-of-Care Molecular Diagnostics POC market, 2021 - 2033 (USD Million)
  • Fig. 51 U.S. Point-of-Care Molecular Diagnostics market: End Use movement analysis
  • Fig. 52 U.S. Point-of-Care Molecular Diagnostics market: End Use outlook and key takeaways
  • Fig. 53 Point-of-Care Molecular Diagnostics Decentralized Labs market, 2021 - 2033 (USD Million)
  • Fig. 54 Point-of-Care Molecular Diagnostics Hospitals market, 2021 - 2033 (USD Million)
  • Fig. 55 Point-of-Care Molecular Diagnostics Home-care market, 2021 - 2033 (USD Million)
  • Fig. 56 Point-of-Care Molecular Diagnostics Assisted Living Healthcare Facilities market, 2021 - 2033 (USD Million)
  • Fig. 57 Point-of-Care Molecular Diagnostics Other uses market, 2021 - 2033 (USD Million)
  • Fig. 58 U.S. Point-of-Care Molecular Diagnostics market share and leading players
  • Fig. 59 U.S. market share and leading players
  • Fig. 60 U.S. SWOT
  • Fig. 61 U.S. market estimates and forecasts, 2021 - 2033
  • Fig. 62 Market share of key market players- U.S. Point-of-Care Molecular Diagnostics market
目次
Product Code: GVR-4-68040-203-1

Market Size & Trends:

The U.S. point of care molecular diagnostics market size was estimated at USD 3.23 billion in 2024 and is expected to grow at a CAGR of 5.45% from 2025 to 2033. The market is centered around rapid and decentralized molecular testing that supports quicker clinical decisions at or near the site of patient care. These diagnostic platforms are increasingly adopted for applications such as infectious disease screening, respiratory tract infections, and sexually transmitted disease detection, driven by the need for immediate and accurate results in outpatient and emergency settings.

Market growth is supported by the rising demand for quick and easy testing outside traditional labs, especially in emergency rooms and clinics. The growing number of infectious disease cases and the need for fast results are pushing the use of point-of-care molecular tests. New technologies, such as portable PCR machines and simple sample processing tools, make these tests more accurate and easier to use. In addition, the focus on faster testing after the COVID-19 pandemic is helping the market grow further.

Moreover, point-of-care molecular diagnostics in primary care settings cover a wide range of uses, from basic glucose tests to more complex blood clotting checks. Many clinics across the U.S. are moving away from traditional lab-based testing to point-of-care methods, which help reduce delays linked to sample handling and transport. This switch allows for quicker decisions during patient visits, leading to faster results, lower costs, and improved care.

In addition, the growing elderly population is expected to support the growth of the U.S. point of care molecular diagnostics industry. Based on the U.S. National Cancer Institute's SEER Database, 38% of women and 43% of men are likely to develop cancer during their lifetime. Nearly two-thirds of all new cancer cases are found in people aged 65 and older, showing that aging increases vulnerability to cancer. Molecular diagnostics play a key role in managing cancer, infectious diseases, and heart conditions, making them an essential part of timely diagnosis and treatment in older adults.

Furthermore, market players are actively developing new point-of-care molecular testing products to address growing diagnostic needs. In April 2023, Curative, Inc., based in Los Angeles, announced the spin-off of Sensible Diagnostics to commercialize a desktop PCR testing platform. This system is designed to deliver lab-quality results in approximately 10 minutes, at a cost similar to lateral flow antigen tests. It is intended for use in retail clinics, urgent care centers, and other near-patient environments.

In August 2023, Sensible Diagnostics received a NIH RADx Tech award of approximately USD 1 million to support the development of a multiplex respiratory viral panel for point-of-care use. These efforts reflect growing investment in rapid, accurate molecular testing solutions that support timely diagnosis and improve clinical workflows across decentralized care settings.

U.S. Point of Care Molecular Diagnostics Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the U.S. point of care molecular diagnostics market report based on application, technology, test location, and end-use:

  • Technology Outlook (Revenue, USD Million, 2021 - 2033)
  • PCR-based
  • Genetic Sequencing-based
  • Hybridization-based
  • Microarray-based
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Infectious Diseases
    • HIV POC
    • Clostridium difficile POC
    • HBV POC
    • Pneumonia or Streptococcus associated infections
    • Respiratory syncytial virus (RSV) POC
    • HPV POC
    • Influenza/Flu POC
    • HCV POC
    • MRSA POC
    • TB and drug-resistant TB POC
    • HSV POC
    • Other Infectious Diseases
  • Oncology
  • Hematology
    • Complete blood count (CBC)
    • Prothrombin time (PT)
    • Partial Thromboplastin Time (PTT)
    • Others
  • Prenatal Testing
  • Endocrinology
  • Other Applications
  • Test Location Outlook (Revenue, USD Million, 2021 - 2033)
  • OTC
  • POC
  • End-use Outlook (Revenue, USD Million, 2021 - 2033)
  • Decentralized Labs
  • Hospitals
  • Home-care
  • Assisted Living Healthcare Facilities
  • Others

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Test Location
    • 1.2.2. Application
    • 1.2.3. Technology
    • 1.2.4. End Use
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in the U.S.
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Test Location and Application Snapshot
    • 2.2.2. Technology Snapshot
    • 2.2.3. End Use Snapshot
  • 2.3. Competitive Insights

Chapter 3. U.S. Point-of-Care Molecular Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Growing demand for rapid and decentralized testing
      • 3.2.1.2. Rising prevalence of infectious diseases
      • 3.2.1.3. Technological advancements in molecular platforms
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost of molecular POC devices and consumables
      • 3.2.2.2. Regulatory and quality assurance challenges
  • 3.3. U.S. Point-of-Care Molecular Diagnostics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Technology Business Analysis

  • 4.1. Point-of-Care Molecular Diagnostics Market: Technology Movement Analysis
  • 4.2. PCR-based
    • 4.2.1. PCR-based market, 2021 - 2033 (USD Million)
  • 4.3. Genetic Sequencing-based
    • 4.3.1. Genetic Sequencing-based market, 2021 - 2033 (USD Million)
  • 4.4. Hybridization-based
    • 4.4.1. Hybridization-based market, 2021 - 2033 (USD Million)
  • 4.5. Microarray-based
    • 4.5.1. Microarray-based market, 2021 - 2033 (USD Million)

Chapter 5. Application Business Analysis

  • 5.1. Point-of-Care Molecular Diagnostics Market: Application Movement Analysis
  • 5.2. Infectious Diseases
    • 5.2.1. Infectious Diseases market, 2021 - 2033 (USD Million)
    • 5.2.2. HIV POC
      • 5.2.2.1. HIV POC market, 2021 - 2033 (USD Million)
    • 5.2.3. Clostridium difficile POC
      • 5.2.3.1. Clostridium difficile POC market, 2021 - 2033 (USD Million)
    • 5.2.4. HBV POC
      • 5.2.4.1. HBV POC market, 2021 - 2033 (USD Million)
    • 5.2.5. Pneumonia or Streptococcus associated infections
      • 5.2.5.1. Pneumonia or Streptococcus associated infections market, 2021 - 2033 (USD Million)
    • 5.2.6. Respiratory Syncytial Virus (RSV) POC
      • 5.2.6.1. Respiratory Syncytial Virus (RSV) POC market, 2021 - 2033 (USD Million)
    • 5.2.7. HPV POC
      • 5.2.7.1. HPV POC market, 2021 - 2033 (USD Million)
    • 5.2.8. Influenza/Flu POC
      • 5.2.8.1. Influenza/Flu POC market, 2021 - 2033 (USD Million)
    • 5.2.9. HCV POC
      • 5.2.9.1. HCV POC market, 2021 - 2033 (USD Million)
    • 5.2.10. MRSA POC
      • 5.2.10.1. MRSA POC market, 2021 - 2033 (USD Million)
    • 5.2.11. TB and drug-resistant TB POC
      • 5.2.11.1. TB and drug-resistant TB POC market, 2021 - 2033 (USD Million)
    • 5.2.12. HSV POC
      • 5.2.12.1. HSV POC market, 2021 - 2033 (USD Million)
    • 5.2.13. Other Infectious Diseases
      • 5.2.13.1. Other Infectious Diseases market, 2021 - 2033 (USD Million)
  • 5.3. Oncology
    • 5.3.1. Oncology market, 2021 - 2033 (USD Million)
  • 5.4. Hematology
    • 5.4.1. Hematology market, 2021 - 2033 (USD Million)
    • 5.4.2. Complete blood count (CBC)
      • 5.4.2.1. Complete blood count (CBC) market, 2021 - 2033 (USD Million)
    • 5.4.3. Prothrombin time (PT)
      • 5.4.3.1. Prothrombin time (PT) market, 2021 - 2033 (USD Million)
    • 5.4.4. Partial Thromboplastin Time (PTT)
      • 5.4.4.1. Partial Thromboplastin Time (PTT) market, 2021 - 2033 (USD Million)
    • 5.4.5. Others
      • 5.4.5.1. Others market, 2021 - 2033 (USD Million)
  • 5.5. Prenatal Testing
    • 5.5.1. Prenatal Testing market, 2021 - 2033 (USD Million)
  • 5.6. Endocrinology
    • 5.6.1. Endocrinology market, 2021 - 2033 (USD Million)
  • 5.7. Others
    • 5.7.1. Others market, 2021 - 2033 (USD Million)

Chapter 6. Test Location Business Analysis

  • 6.1. Point-of-Care Molecular Diagnostics Market: Test Location Movement Analysis
  • 6.2. OTC
    • 6.2.1. OTC market, 2021 - 2033 (USD Million)
  • 6.3. POC
    • 6.3.1. POC market, 2021 - 2033 (USD Million)

Chapter 7. End Use Business Analysis

  • 7.1. Point-of-Care Molecular Diagnostics Market: End Use Movement Analysis
  • 7.2. Decentralized Labs
    • 7.2.1. Decentralized Labs market, 2021 - 2033 (USD Million)
  • 7.3. Hospitals
    • 7.3.1. Hospitals market, 2021 - 2033 (USD Million)
  • 7.4. Home-care
    • 7.4.1. Home-care market, 2021 - 2033 (USD Million)
  • 7.5. Assisted Living Healthcare Facilities
    • 7.5.1. Assisted Living Healthcare Facilities market, 2021 - 2033 (USD Million)
  • 7.6. Others
    • 7.6.1. Others market, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
    • 8.2.1. New Products and Services Launch
    • 8.2.2. Partnerships
    • 8.2.3. Acquisition
    • 8.2.4. Collaboration
    • 8.2.5. Funding
  • 8.3. Key Company Market Share Analysis, 2024
  • 8.4. Company Heat Map Analysis
  • 8.5. Company Profiles
    • 8.5.1. QIAGEN
      • 8.5.1.1. Company Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Products and Services Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. DANAHER
      • 8.5.2.1. Company Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Products and Services Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. THERMO FISHER SCIENTIFIC, INC.
      • 8.5.3.1. Company Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Products and Services Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. BD
      • 8.5.4.1. Company Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Products and Services Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. F. HOFFMAN-LA ROCHE AG
      • 8.5.5.1. Company Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Products and Services Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. CHARLES RIVER LABORATORIES
      • 8.5.6.1. Company Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Products and Services Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. QUEST DIAGNOSTICS INCORPORATED
      • 8.5.7.1. Company Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Products and Services Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. BIO-RAD LABORATORIES, INC.
      • 8.5.8.1. Company Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Products and Services Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. HOLOGIC INC.
      • 8.5.9.1. Company Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Products and Services Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. AGILENT TECHNOLOGIES, INC.
      • 8.5.10.1. Company Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Products and Services Benchmarking
      • 8.5.10.4. Strategic Initiatives